Cargando…
Choosing pharmacotherapy for ILD in patients with connective tissue disease
Interstitial lung disease (ILD) is a well-recognised complication of several connective tissue diseases (CTD). This article outlines the various treatment options for the most common CTD-ILDs and discuss the ongoing research in this field. https://bit.ly/39NHwx6
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753625/ https://www.ncbi.nlm.nih.gov/pubmed/35035571 http://dx.doi.org/10.1183/20734735.0114-2021 |
| _version_ | 1784632130359263232 |
|---|---|
| author | Wu, Zhe Molyneaux, Philip L. |
| author_facet | Wu, Zhe Molyneaux, Philip L. |
| author_sort | Wu, Zhe |
| collection | PubMed |
| description | Interstitial lung disease (ILD) is a well-recognised complication of several connective tissue diseases (CTD). This article outlines the various treatment options for the most common CTD-ILDs and discuss the ongoing research in this field. https://bit.ly/39NHwx6 |
| format | Online Article Text |
| id | pubmed-8753625 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Respiratory Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87536252022-01-13 Choosing pharmacotherapy for ILD in patients with connective tissue disease Wu, Zhe Molyneaux, Philip L. Breathe (Sheff) Expert Opinion Interstitial lung disease (ILD) is a well-recognised complication of several connective tissue diseases (CTD). This article outlines the various treatment options for the most common CTD-ILDs and discuss the ongoing research in this field. https://bit.ly/39NHwx6 European Respiratory Society 2021-12 /pmc/articles/PMC8753625/ /pubmed/35035571 http://dx.doi.org/10.1183/20734735.0114-2021 Text en Copyright ©ERS 2021 https://creativecommons.org/licenses/by-nc/4.0/Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
| spellingShingle | Expert Opinion Wu, Zhe Molyneaux, Philip L. Choosing pharmacotherapy for ILD in patients with connective tissue disease |
| title | Choosing pharmacotherapy for ILD in patients with connective tissue disease |
| title_full | Choosing pharmacotherapy for ILD in patients with connective tissue disease |
| title_fullStr | Choosing pharmacotherapy for ILD in patients with connective tissue disease |
| title_full_unstemmed | Choosing pharmacotherapy for ILD in patients with connective tissue disease |
| title_short | Choosing pharmacotherapy for ILD in patients with connective tissue disease |
| title_sort | choosing pharmacotherapy for ild in patients with connective tissue disease |
| topic | Expert Opinion |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753625/ https://www.ncbi.nlm.nih.gov/pubmed/35035571 http://dx.doi.org/10.1183/20734735.0114-2021 |
| work_keys_str_mv | AT wuzhe choosingpharmacotherapyforildinpatientswithconnectivetissuedisease AT molyneauxphilipl choosingpharmacotherapyforildinpatientswithconnectivetissuedisease |